+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biopharmaceutical CMO & CRO Market Size Analysis Report By Source, By Service Type (Contract Manufacturing, Contract Research), By Product (Biologics, Biosimilars), And Segment Forecasts, 2019 - 2025

  • ID: 4375440
  • Report
  • 240 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • AbbVie, Inc.
  • BIOMEVA GmbH
  • ICON plc
  • JRS PHARMA
  • PRA Health Sciences
  • Samsung BioLogics
  • MORE
The global biopharmaceutical cmo & cro market size is expected to reach USD 37.8 billion by 2025, at a CAGR of 7.7%, according to this report. The market is significantly driven by the growing interest of conventional drug developers in biological therapeutics. At present, outsourcing has become a cost-saving strategy for small to medium sized biomanufacturers, as it helps eliminate the need for establishing expensive specialized facilities or hiring and training personnel.

The decline in R&D productivity and increased development costs has resulted in high pressure on biopharmaceutical manufacturers pertaining to short-term earnings and profit margins. This, in turn, has created lucrative opportunities for the Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) to accelerate their business operations.

Robustness of venture capital investments is one of the important supportive factors that have created growth opportunities for CMOs. Venture capital funds are considered more reliable than public equity. Increasing availability of venture funds for life sciences is expected to further bolster the growth of CMOs. However, these CMOs and CROs are facing competition from in-house departments of pharmaceutical and biotechnology companies. Several big pharma companies like Novartis announced to keep their biomanufacturing process in-house.

Mammalian cell line-based bioproduction systems held the largest market share in terms of revenue in 2018. Factors responsible for this estimated share include growth in mammalian system titers and yields. CMOs are engaged in standardizing their mammalian systems, thereby driving the revenue growth of the segment. Contract research service is anticipated to be the fastest growing segment over the forecast period, attributed to increasing investment in research programs for development of novel therapeutics. The CMOs are majorly benefitted by the continuous market expansion of biologics.

Several biopharma companies from U.S. are considering Asian countries for development of pharma products. This is primarily due to the growing costs of R&D in their home country and the presence of low-cost production facilities and cheap labor in Asian countries. The key players are also involved in establishing mutually beneficial alliances with other emerging CMOs to scale up their production capabilities.

Further key findings from the report suggest:
  • Mammalian cell line-based bioproduction system accounted for the largest market share in terms of revenue in 2018
  • Plant-based expression systems are developed and explored as a cost-effective alternative for the production of large molecules
  • Contract manufacturing services accounted for the largest market share owing to the presence of wide range of services from cell line development to final packaging of the product
  • In recent times, biologics manufacturing is becoming more specialized, as a result, CMOs have become an integral part of the biologics production strategies of clients, leading to biologics gaining a large share of the biopharmaceutical CMO & CRO market
  • North America biopharmaceutical research industry is recognized as a leader in biopharmaceutical innovations, thereby resulting in the large share of this region
  • Some key CMOs are Lonza, Boehringer Ingelheim GmbH, Patheon, Samsung BioLogics, FUJIFILM Diosynth Biotechnologies U.S.A., Inc.


Please Note: This report will be delivered within 3 business days of ordering.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie, Inc.
  • BIOMEVA GmbH
  • ICON plc
  • JRS PHARMA
  • PRA Health Sciences
  • Samsung BioLogics
  • MORE
Chapter 1 Research Methodology & Scope
1.1 Market Segmentation & Scope
1.2 Market Definition
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 Internal database
1.3.3 Secondary sources & third party perspectives
1.3.4 Primary research
1.4 Information Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Data Visualization
1.6 Data Validation & Publishing

Chapter 2 Executive Summary
2.1 Biopharmaceutical CMO & CRO Market Outlook, 2014 - 2025
2.2 Biopharmaceutical CMO & CRO Market : Segment Outlook, 2014 - 2025
2.3 Biopharmaceutical CMO & CRO Market : Competitive Insights

Chapter 3 Biopharmaceutical CMO & CRO Market Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2 Penetration & Growth Prospect Mapping, 2018
3.3 Product Pipeline Analysis, by Stage
3.4 Cost Structure Analysis
3.5 User Perspective Analysis
3.5.1. Consumer behavior analysis
3.5.2. Market influencer analysis
3.6 Procedure Cost Analysis/Breakdown
3.7 List of Key End-users By Region, By Service Type, By Country
3.8 Technology Overview
3.9.3. Technology timeline
3.9 Regulatory Framework
3.9.1. Reimbursement framework
3.9.2. Standards & compliances
3.10 Biopharmaceutical CMO & CRO Market - Market Dynamics
3.10.1 Market driver analysis
3.10.1.1 Rising investment by CMOs for capacity expansion
3.10.1.2 Commercial success of biopharmaceuticals and consequent increased demand for the biopharmaceuticals
3.10.1.3 Robust biopharmaceuticals pipeline
3.10.1.4 Cost and time saving benefits offered by contract services
3.10.2 Market restraint analysis
3.10.2.1 Limited outsourcing amongst well-stablished biopharmaceutical manufacturer
3.10.3 Market challenges analysis
3.10.3.1 Well established players are expanding their in-house biologic development procedures
3.11 Biopharmaceutical CMO & CRO Market Analysis Tools
3.11.1 Industry Analysis - Porter’s
3.11.1.1 Supplier Power: Substantial number of suppliers for bioprocessing equipment contributes to the low supplier power
3.11.1.2 Buyer Power: Fragmaneted nature of biopharmaceutical industry led to moderate bargaining power of buyers
3.11.1.3 Substitution Threat: High due to presence of large number big pharma companies
3.11.1.4 New Entrants Threat: Presence of established players coupled with need of adequate capacity results in moderate threat of new entrants
3.11.1.5 Competitive rivalry: High competitive rivalry amomg key players owing to significant number of merger & acquisitions and strategic alliances among biopharmaceutical developers
3.11.2 PESTEL analysis
3.11.2.1 Political landscape
3.11.2.2 Environmental landscape
3.11.2.3 Social landscape
3.11.2.4 Technology landscape
3.11.2.5 Legal landscape
3.11.3 Major deals & strategic alliances analysis
3.11.3.1 Joint ventures
3.11.3.2 Mergers & acquisitions
3.11.3.3 Licensing & partnership
3.11.3.4 Technology collaborations
3.11.3.5 Strategic divestments
3.11.4 Market entry strategies
3.11.5 Case studies
3.12 Trends in Biopharmaceutical Industry
3.13 R&D Landscape of Biopharmaceuticals
3.14 Customer Relationship Management in Contract Manufacturing
3.14.1 Selection process of CMO
3.14.2 Operations and quality oversight of CMOs

Chapter 4 Biopharmaceutical CMO & CRO Market: Competitive Analysis
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.2 Company/Competition Categorization
4.3 Vendor Landscape
4.3.1 List of key distributors and channel partners
4.3.2 Key customers
4.3.3 Key company market share analysis, 2018
4.4 Public Companies
4.4.1 Company market position analysis
4.4.2 Company market share/ranking by region
4.4.3 Competitive dashboard analysis
4.4.4 Market differentiators
4.4.5 Synergy analysis: Major deals & strategic alliances
4.5 Private Companies
4.5.1 List of key emerging companies
4.5.2 Funding outlook
4.5.3 Regional network map
4.5.4 Company market position analysis
4.5.5 Supplier Ranking

Chapter 5 Biopharmaceuticals CMO & CRO Market: Source Estimates & Trend Analysis
5.1 Definitions & Scope
5.2 Source Market Share Analysis, 2018 & 2025
5.3 Biopharmaceuticals CMO & CRO Market: Source Movement Analysis, 2018 & 2025
5.4 Global Biopharmaceuticals CMO & CRO Market, by Source, 2014 to 2025
5.5 Market Size & Forecasts and Trend Analyses, 2014 to 2025 for the following,
5.5.1 Mammalian source
5.5.1.1 Global mammalian source market, 2014 - 2025 (USD Million)
5.5.2 Non-mammalian Source
5.5.2.1 Global non-mammalian source market, 2014 - 2025 (USD
5.6 Biopharmaceuticals CMO & CRO Source Market, by Product, 2014 to 2025

Chapter 6 Biopharmaceuticals CMO & CRO Market: Service Type Estimates & Trend Analysis
6.1. Definitions & Scope
6.2. Service Type Market Share Analysis, 2018 & 2025
6.3 Biopharmaceuticals CMO & CRO Market: Service Type Movement Analysis, 2018 & 2025
6.4. Global Biopharmaceuticals CMO & CRO Market, by Service Type, 2014 to 2025
6.5 Market Size & Forecasts and Trend Analyses, 2014 to 2025 for the following,
6.5.1 Contract manufacturing, by service
6.5.1.1 Global contract manufacturing market, 2014 - 2025 (USD Million)
6.5.1.2 Process development
6.5.1.2.1 Global process development market, 2014 - 2025 (USD Million)
6.5.1.2.2 Downstream processing
6.5.1.2.2.1 Global downstream processing market, 2014 - 2025 (USD Million)
6.5.1.2.3 Upstream processing
6.5.1.2.3.1 Global upstream processing market, 2014 - 2025 (USD Million)
6.5.1.3 Process development
6.5.1.3.1 Global process development market, 2014 - 2025 (USD Million)
6.5.1.4 Fill & finish operations
6.5.1.4.1 Global fill & finish operations market, 2014 - 2025 (USD Million)
6.5.1.5 Analytical & QC testing
6.5.1.5.1 Global analytical & QC testing market, 2014 - 2025 (USD Million)
6.5.1.6 Packaging
6.5.1.6.1 Global contract packaging market, 2014 - 2025 (USD Million)
6.5.2 Contract research
6.5.2.1 Global contract research market, 2014 - 2025 (USD Million)
6.5.2.2 Oncology
6.5.1.2.1 Global oncology market, 2014 - 2025 (USD Million)
6.5.2.3 Inflammation & immunology
6.5.2.3.1 Global inflammation & immunology market, 2014 - 2025 (USD Million)
6.5.2.4 Cardiology
6.5.2.4.1 Global cardiology market, 2014 - 2025 (USD Million)
6.5.2.5 Neuroscience
6.5.1.5.1 Global neuroscience market, 2014 - 2025 (USD Million)
6.5.2.6 Others
6.5.1.6.1 Global other CRO services market, 2014 - 2025 (USD Million)

Chapter 7 Biopharmaceuticals CMO & CRO Market: Product Estimates & Trend Analysis
7.1. Definitions & Scope
7.2. Product Market Share Analysis, 2018 & 2025
7.3 Biopharmaceuticals CMO & CRO Market: Product Movement Analysis, 2018 & 2025
7.4. Global Biopharmaceuticals CMO & CRO Market, by Product, 2014 to 2025
7.5 Market Size & Forecasts and Trend Analyses, 2014 to 2025 for the following,
7.5.1 Biologics
7.5.1.1 Global biologics market, 2014 - 2025 (USD Million)
7.5.1.2 Monoclonal antibodies
7.5.1.2.1 Global monoclonal antibodies market, 2014 - 2025 (USD Million)
7.5.1.3 Recombinant proteins
7.5.1.3.1 Global recombinant proteins market, 2014 - 2025 (USD Million)
7.5.1.4 Vaccines
7.5.1.4.1 Global vaccines market, 2014 - 2025 (USD Million)
7.5.1.5 Antisense, RNAi, & molecular therapy
7.5.1.5.1 Global antisense, RNAi, & molecular therapy market, 2014 - 2025 (USD Million)
7.5.1.6 Others
7.5.1.7.1 Global other product market, 2014 - 2025 (USD Million)
7.5.2 Biosimilars
7.5.2.1 Global biosimilars market, 2014 - 2025 (USD Million)

Chapter 8 Biopharmaceuticals CMO & CRO Market: Regional Estimates & Trend Analysis, by Source, Service Type, & Product
8.1 Biopharmaceuticals CMO & CRO Market Share by Region, 2018 & 2025
8.2 Regional Market Share and Leading Players, 2018
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa
8.3 North America
8.3.1 North America biopharmaceuticals CMO & CRO market, 2014 - 2025 (USD Million)
8.3.2 U.S.
8.3.2.1 U.S. biopharmaceuticals CMO & CRO market, by source, 2014 - 2025 (USD Million)
8.3.2.2 U.S. biopharmaceuticals CMO & CRO market, by service type, 2014 - 2025 (USD Million)
8.3.2.3 U.S. biopharmaceuticals CMO & CRO market, by product, 2014 - 2025 (USD Million)
8.3.3 Canada
8.3.3.1 Canada biopharmaceuticals CMO & CRO market, by source, 2014 - 2025 (USD Million)
8.3.3.2 Canada biopharmaceuticals CMO & CRO market, by service type, 2014 - 2025 (USD Million)
8.3.3.3 Canada biopharmaceuticals CMO & CRO market, by product, 2014 - 2025 (USD Million)
8.4 Europe
8.4.1 Europe biopharmaceuticals CMO & CRO market, 2014 - 2025 (USD Million)
8.4.2 Germany
8.4.2.1 Germany biopharmaceuticals CMO & CRO market, by source, 2014 - 2025 (USD Million)
8.4.2.2 Germany biopharmaceuticals CMO & CRO market, by service type, 2014 - 2025 (USD Million)
8.4.2.3 Germany biopharmaceuticals CMO & CRO market, by product, 2014 - 2025 (USD Million)
8.4.3 France
8.4.3.1 France biopharmaceuticals CMO & CRO market, by source, 2014 - 2025 (USD Million)
8.4.3.2 France biopharmaceuticals CMO & CRO market, by service type, 2014 - 2025 (USD Million)
8.4.3.3 France biopharmaceuticals CMO & CRO market, by product, 2014 - 2025 (USD Million)
8.5 Asia Pacific
8.5.1 Asia Pacific biopharmaceuticals CMO & CRO market, 2014 - 2025 (USD Million)
8.5.2 China
8.5.2.1 China biopharmaceuticals CMO & CRO market, by source, 2014 - 2025 (USD Million)
8.5.2.2 China biopharmaceuticals CMO & CRO market, by service type, 2014 - 2025 (USD Million)
8.5.2.3 China biopharmaceuticals CMO & CRO market, by product, 2014 - 2025 (USD Million)
8.5.3 India
8.5.3.1 India biopharmaceuticals CMO & CRO market, by source, 2014 - 2025 (USD Million)
8.5.3.2 India biopharmaceuticals CMO & CRO market, by service type, 2014 - 2025 (USD Million)
8.5.3.3 India biopharmaceuticals CMO & CRO market, by product, 2014 - 2025 (USD Million)
8.6 Latin America
8.6.1 Latin America biopharmaceuticals CMO & CRO market, 2014 - 2025 (USD Million)
8.6.2 Brazil
8.6.2.1 Brazil biopharmaceuticals CMO & CRO market, by source, 2014 - 2025 (USD Million)
8.6.2.2 Brazil biopharmaceuticals CMO & CRO market, by service type, 2014 - 2025 (USD Million)
8.6.2.3 Brazil biopharmaceuticals CMO & CRO market, by product, 2014 - 2025 (USD Million)
8.7 Middle East & Africa (MEA)
8.7.1 Middle East & Africa biopharmaceuticals CMO & CRO market, 2014 - 2025 (USD Million)
8.7.2 South Africa
8.7.2.1 South Africa biopharmaceuticals CMO & CRO market, by source, 2014 - 2025 (USD Million)
8.7.2.2 South Africa biopharmaceuticals CMO & CRO market, by service type, 2014 - 2025 (USD Million)
8.7.2.3 South Africa biopharmaceuticals CMO & CRO market, by product, 2014 - 2025 (USD Million)

Chapter 9 Competitive Landscape
9.1 Strategy Framework
9.2 Market Participation Categorization
9.3 Company Profiles
9.1.1 Boehringer Ingelheim GmbH
9.1.1.1 Company overview
9.1.1.2 Financial performance
9.1.1.3 Product benchmarking
9.1.1.4 Strategic initiatives
9.1.2 Lonza
9.1.2.1 Company overview
9.1.2.2 Financial performance
9.1.2.3 Product benchmarking
9.1.2.4 Strategic initiatives
9.1.3 Inno Biologics Sdn Bhd
9.1.3.1 Company overview
9.1.3.2 Financial performance
9.1.3.3 Product benchmarking
9.1.3.4 Strategic initiatives
9.1.4 Rentschler Biotechnologie SE
9.1.4.1 Company overview
9.1.4.2 Financial performance
9.1.4.3 Product benchmarking
9.1.4.4 Strategic initiatives
9.1.5 JRS PHARMA
9.1.5.1 Company overview
9.1.5.1.1 CELONIC AG
9.1.5.2 Financial performance
9.1.5.2.1 Financial performance
9.1.5.3 Product benchmarking
9.1.5.4 Strategic initiatives
9.1.6 BIOMEVA GmbH
9.1.6.1 Company overview
9.1.6.2 Financial performance
9.1.6.3 Product benchmarking
9.1.6.4 Strategic initiatives
9.1.7 ProBioGen AG
9.1.7.1 Company overview
9.1.7.2 Financial performance
9.1.7.3 Product benchmarking
9.1.7.4 Strategic initiatives
9.3.8 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
9.3.8.1 Company overview
9.3.8.2 Financial performance
9.3.8.3 Product benchmarking
9.3.8.4 Strategic initiatives
9.3.9 TOYOBO CO., LTD.
9.3.9.1 Company overview
9.3.9.2 Financial performance
9.3.9.3 Product benchmarking
9.3.9.4 Strategic initiatives
9.3.10 Samsung BioLogics
9.3.10.1 Company overview
9.3.10.2 Financial performance
9.3.10.3 Product benchmarking
9.3.10.4 Strategic initiatives
9.3.11 Thermo Fisher Scientific Inc.(Patheon)
9.3.11.1 Company overview
9.3.11.1.1 DPx
9.3.11.2 Financial performance
9.3.11.3 Product benchmarking
9.3.11.4 Strategic initiatives
9.3.12 AGC Biologics (CMC Biologics)
9.3.12.1 Company overview
9.3.12.2 Financial performance
9.3.12.3 Product benchmarking
9.3.12.4 Strategic initiatives
9.3.13 Binex Co., Ltd.
9.3.13.1 Company overview
9.3.13.2 Financial performance
9.3.13.3 Product benchmarking
9.3.13.4 Strategic initiatives
9.3.14 WuXi Biologics
9.3.14.1 Company overview
9.3.14.2 Financial performance
9.3.14.3 Product benchmarking
9.3.14.4 Strategic initiatives
9.3.15 AbbVie, Inc.
9.3.15.1 Company overview
9.3.15.2 Financial performance
9.3.15.3 Product benchmarking
9.3.15.4 Strategic initiatives
9.3.16 Charles River Laboratories International, Inc
9.3.16.1 Company overview
9.3.16.2 Financial performance
9.3.16.3 Product benchmarking
9.3.16.4 Strategic initiatives
9.3.17 ICON plc
9.3.17.1 Company overview
9.3.17.2 Financial performance
9.3.17.3 Product benchmarking
9.3.17.4 Strategic initiatives
9.3.18 Pharmaceutical Product Development, LLC
9.3.18.1 Company overview
9.3.18.2 Financial performance
9.3.18.3 Product benchmarking
9.3.18.4 Strategic initiatives
9.3.19 Laboratory Corporation of America Holdings
9.3.19.1 Company overview
9.3.19.2 Financial performance
9.3.19.3 Product benchmarking
9.3.19.4 Strategic initiatives
9.3.20 PAREXEL International Corporation
9.3.20.1 Company overview
9.3.20.2 Financial performance
9.3.20.3 Product benchmarking
9.3.20.4 Strategic initiatives
9.3.21 PRA Health Sciences
9.3.21.1 Company overview
9.3.21.2 Financial performance
9.3.21.3 Product benchmarking
9.3.21.4 Strategic initiatives
9.4 List of Companies

*Full List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Boehringer Ingelheim GmbH
  • Lonza
  • Inno Biologics Sdn Bhd
  • Rentschler Biotechnologie SE
  • JRS PHARMA
  • BIOMEVA GmbH
  • ProBioGen AG
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • TOYOBO CO., LTD.
  • Samsung BioLogics
  • Thermo Fisher Scientific Inc.(Patheon)
  • AGC Biologics (CMC Biologics)
  • Binex Co., Ltd.
  • WuXi Biologics
  • AbbVie, Inc.
  • Charles River Laboratories International, Inc
  • ICON plc
  • Pharmaceutical Product Development, LLC
  • Laboratory Corporation of America Holdings
  • PAREXEL International Corporation
  • PRA Health Sciences
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4375440
Adroll
adroll